Overview

* Alector ( ALEC ) Q2 collaboration revenue declines to $7.9 mln from $15.1 mln year-over-year

* Net loss narrows to $30.5 mln from $38.7 mln in Q2 2024

* Cash reserves of $307.3 mln expected to fund operations into H2 2027

Outlook

* Alector ( ALEC ) expects 2025 collaboration revenue between $13 mln and $18 mln

* Alector ( ALEC ) anticipates 2025 R&D expenses between $130 mln and $140 mln

* Alector ( ALEC ) sees 2025 G&A expenses between $55 mln and $65 mln

* Company has cash runway into the second half of 2027

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $7.87

Revenue mln

Q2 EPS -$0.3

Q2 Net -$30.52

Income mln

Q2 Basic -$0.3

EPS

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and 2 "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Alector Inc ( ALEC ) is $3.75, about 61.9% above its August 6 closing price of $1.43

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)